Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 19Lymphoid 17Other solid neoplasm 13Gastrointestinal 7Genitourinary 5Plasma cell 3Sarcoma 2Gynecologic 2Dermatologic 2Classical hematology 2Breast 2Thoracic 1Head & Neck 1CNS 1

Conditions

Breast Neoplasms, Male 2Breast Neoplasms 2

Interventions

Cyclophosphamide 80Paclitaxel 53Trastuzumab 41Tamoxifen 40Doxorubicin 39Specimen Handling 35Docetaxel 35Magnetic Resonance Spectroscopy 34Radiotherapy 33Taxes 30Fluorouracil 26Chemotherapy, Adjuvant 26Carboplatin 24Epirubicin 22Biopsy 22Filgrastim 21Neoadjuvant Therapy 19Methotrexate 19aldesleukin 17Peripheral Blood Stem Cell Transplantation 16Bevacizumab 14Anastrozole 14exemestane 13Lapatinib 13veliparib 12CMF regimen 12sargramostim 11Goserelin 11Fulvestrant 11Capecitabine 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × alvocidib × Breast × Clear all
NCT00020332 2013-06-17

Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00039455 2013-02-01

Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
50 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡